Richard Viebahn

Richard Viebahn

Auto-generated profile, based on publicly available information

Richard Viebahn

Department of Surgery, University Hospital Knappschaftskrankenhaus Bochum, Ruhr-University Bochum, 44892 Bochum, Germany

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2016 in Molecular Oncology
Verified
Journal Article
Open access
PDF file
WSWolff Schmiegel
Wolff Schmiegel
Rodney ScottRodney Scott
Rodney Scott
SDSusan Dooley
Susan Dooley
WLWendy Lewis
Wendy Lewis
CMCliff J. Meldrum
Cliff J. Meldrum
SFStephen Fox
Stephen Fox
An accurate blood‐based RAS mutation assay to determine eligibility of metastatic colorectal cancer (mCRC) patients for anti‐EGFR therapy would benefit clinical practice by better informing decisions to administer treatment independent of tissue availability. The objective of this study was to determine the level of concordance between plasma and tissue RAS mutation status in patients with mCRC to gauge whether blood‐based RAS mutation testing is a viable alternative to standard‐of‐care RAS tumor testing. RAS testing was performed on plasma samples from newly diagnosed metastatic patients, or from recurrent mCRC patients using the highly sensitive digital PCR technology, BEAMing (beads, emulsions, amplification, and magnetics), and compared with DNA sequencing data of respective FFPE (formalin‐fixed paraffin‐embedded) tumor samples. Discordant tissue RAS results were re‐examined by BEAMing, if possible. The prevalence of RAS mutations detected in plasma (51%) vs. tumor (53%) was similar, in accord with the known prevalence of RAS mutations observed in mCRC patient populations. The positive agreement between plasma and tumor RAS results was 90.4% (47/52), the negative agreement was 93.5% (43/46), and the overall agreement (concordance) was 91.8% (90/98). The high concordance of plasma and tissue results demonstrates that blood‐based RAS mutation testing is a viable alternative to tissue‐based RAS testing.

1 September 2000 in Radiology
Verified
Journal Article
Closed access
TNThomas Naegele
Thomas Naegele
WGWolfgang Grodd
Wolfgang Grodd
RVRichard Viebahn
Richard Viebahn
USUwe Seeger
Uwe Seeger
UKUwe Klose
Uwe Klose
KVKarsten Voigt
Karsten Voigt
PURPOSE: To evaluate changes in hydrogen 1 magnetic resonance (MR) spectroscopic findings in overt or subclinical hepatic encephalopathy (HE) after liver transplantation and to compare these changes with clinical outcomes and basal ganglia high signal intensity (BGH). MATERIALS AND METHODS: Twenty-two patients scheduled for liver transplantation and 17 healthy control subjects were examined with 1H MR spectroscopy and standard nonenhanced MR imaging. Eight patients underwent complete MR imaging and 1H spectroscopic examinations before liver transplantation and at 3–4-week, 12–28-week, and 10–12-month follow-up after liver transplantation. RESULTS: Before liver transplantation, typical 1H spectroscopic changes—decreased myo-inositol (mI)/creatine (Cr) and choline (Cho)/Cr ratios and an elevated glutamine and glutamate (Glx)/Cr ratio—were found in 21 patients. Eighteen patients had BGH at T1-weighted imaging. Three to 7 months after liver transplantation, the mI/Cr and Glx/Cr ratios were within the normal r...

25 August 2007 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
SWStefan M. Weiner
Stefan M. Weiner
LSLorenz Sellin
Lorenz Sellin
OVOliver Vonend
Oliver Vonend
PSPeter Schenker
Peter Schenker
NBNikolaus J. Buchner
Nikolaus J. Buchner
LRLars C. Rump
Lars C. Rump
Background. The introduction of sirolimus as an immunosuppressive drug for renal transplantation has lead to an increase of unexplained interstitial pneumonitis.

13 October 2010 in Transplant International
Verified
Journal Article
Closed access
PDF file
PSPeter Schenker
Peter Schenker
OVOliver Vonend
Oliver Vonend
BKBernd Krüger
Bernd Krüger
TKThomas Klein
Thomas Klein
SMStefan Michalski
Stefan Michalski
RVRichard Viebahn
Richard Viebahn
Aging of the population and improvements in diabetes therapy have led to an increased number of older pancreas transplant candidates. The aim of our retrospective study was to evaluate pancreas transplantation (PT) outcomes in patients ≥ 50 years, as limited data exist in these patients. We analyzed 398 consecutive pancreas transplant patients from June 1994 to June 2009 for different outcomes (patient/graft survival, rejection rate, and surgical complications) between the age groups ≥ 50 years (n = 69) and <50 years (n = 329). Donor and recipient characteristics were similar except for recipient age (54.0 vs. 38.8 years), BMI (24.6 vs. 22.9 kg/m(2) ), and duration of diabetes mellitus (36.0 vs. 27.7 years). One-, 5-, and 10-year patient and graft (kidney/pancreas) survival were not significantly different between the groups with patient survival rates reaching 84% and pancreas graft survival up to 67% after 10 years. Surgical complications such as relaparotomy rate (34% vs. 33%) or pancreas graft thrombosis (14% vs. 11%) as well as 1-year rejection rates (35% vs. 31%) were not significantly different. PT in selected patients aged ≥ 50 years resulted in survival comparable with that of younger patients. In conclusion, advanced age should no longer be considered as an exclusion criterion for PT. However, good medical assessment and careful patient selection are necessary.

1 April 2000 in Journal of Cardiovascular Pharmacology
Verified
Journal Article
Closed access
DADorothea I. Axel
Dorothea I. Axel
RRReimer Riessen
Reimer Riessen
HRHeike Runge
Heike Runge
RVRichard Viebahn
Richard Viebahn
KKKarl R. Karsch
Karl R. Karsch
Statins competitively inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity reducing mevalonate synthesis. In this study, antiproliferative and antimigratory effects of the new compound cerivastatin were analyzed and compared with classic statins of the first and second generation using mono- and cocultures of human arterial smooth muscle (haSMC) and endothelial (haEC) cells. Effects on the mitotic index and mitochondrial activity of haEC and haSMC monocultures were tested using BrdU enzyme-linked immunosorbent assay (ELISA) and 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) tests, respectively. In lactate dehydrogenase (LDH) assays, cytotoxicity of statins was studied. Transfilter cocultures were performed for 14 days to evaluate haSMC growth under the stimulatory effect of proliferating haEC, which release growth factors [e.g., platelet-derived growth factor (PDGF)]. The hydrophobic statins simvastatin, lovastatin, and atorvastatin significantly inhibited haSMC and haEC growth in monocultures at 0.5-50 μM. However, most potent effects were exerted by cerivastatin in 10- to 30-fold lower doses without any significant cytotoxicity. More important, cerivastatin showed also significant effects on haSMC proliferation and migration in transfilter cocultures at extremely low doses (IC50, 0.04-0.06 μM), even when applied exclusively to the endothelial side and in the presence of low-density lipoprotein (LDL). Addition of mevalonate abolished the effects of cerivastatin completely. Even in the presence of growth-stimulating haEC and LDL, cerivastatin was found to be the most potent inhibitor of haSMC proliferation and migration in doses that also can be reached in human serum after oral drug administration. The results support the concept that statins seems to influence additional cellular mechanisms beyond cholesterol reduction, which might also have a relevance for the prevention of restenosis.

15 April 2006 in Transplantation
Verified
Journal Article
Closed access
VGValeria Gärtner
Valeria Gärtner
TEThomas Eigentler
Thomas Eigentler
RVRichard Viebahn
Richard Viebahn
Background. Renal transplantation is the most effective therapy in end-stage renal disease. The prognosis of transplant survival is still determined by rejection. Morphologically, this involves interstitial rejection with potential development of vascular rejection (VR) and/or glomerular rejection processes, designated as transplant glomerulopathy (TGP). The cellular infiltrates are usually dominated by lymphocytes and macrophages in differing quantity, characterizing the severity of the rejection processes. Methods. In 14% of the renal transplant biopsies and explants in our investigation (n=399) plasma cells (PR) predominate in the cellular infiltrate. To determine whether the enrichment of PR has an impact on graft function or could even constitute an independent parameter for transplant survival, we analyzed 109 cases of transplanted patients matched for AR and CR and divided them into those rich and those nonrich in PR. Results. In the group rich in PR, PR comprised 30% of all infiltrates in comparison to 5% in the group non-rich in PR. VR and TGP appeared significantly more often in PR-rich rejections (P=0.0044). The group rich in PR had a significantly more adverse prognosis (P=0.0024), especially if PR enrichment was observed in the chronic rejection processes (P=0.0148). In the Cox proportional hazard model the occurrence of VR was the only independent factor. Conclusion. In itself, plasma-cell enrichment is not a prognostic marker, but it is an indicator of a more adverse outcome because it is often accompanied by the appearance or subsequent development of VR±TGP. The detection of PR-rich rejection processes should therefore encourage the clinician to intensify the immunosuppressive schedule.